Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used to treat schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market. Its therapeutic use is listed as antipsychotics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include SerLect, Serdolect and Sertindol. Its PubChem CID is 60149.
Sertindole
| CAS No | 106516-24-9 |
|---|---|
| Molecular Formula | C24H26ClFN4O |
| Molecular Weight | 440.9 g/mol |
| Synonyms | 1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used to treat schizophrenia.
The listed CAS number is 106516-24-9.
The listed molecular formula is C24H26ClFN4O.
The listed molecular weight is 440.9 g/mol.
1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one.
The source lists SerLect, Serdolect and Sertindol.